CDT Equity CDT
NASDAQ CDT
$0.34 -0.26 (-42.98%)
As of: Sep 10, 2026 · 2:20 PM EDT

CDT Equity (CDT) Non Operating Interest Expenses (2022 - 2026)

CDT Equity's (CDT) quarterly Non Operating Interest Expenses came in at $1.5 million in Q2 2026, up 50.15% on a YoY basis from $1.0 million in Q2 2025, and up 429.66% quarter-over-quarter from $290000.0 in Q1 2026.

Analysis

CDT Equity (CDT) Non Operating Interest Expenses (2022 - 2026) Analysis & Trends

CDT Equity (CDT) has reported Non Operating Interest Expenses for 5 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Non Operating Interest Expenses rose 50.15% year-over-year to $1.5 million; the trailing twelve-month figure through Jun 2026 stood at $1.9 million (down 62.48% YoY), and the FY2025 full-year result was $3.1 million, down 46.9% from the prior year.
  • Non Operating Interest Expenses advanced to $1.5 million in Q2 2026 per CDT's latest filing, from $290000.0 in the prior quarter.
  • Across five years, Non Operating Interest Expenses topped out at $2.3 million in Q2 2024 and bottomed at -$151000.0 in Q4 2025.
  • Historically, Non Operating Interest Expenses has averaged $833937.5 across 5 years, with a median of $666500.0 in 2024.
  • The sharpest annual moves came in 2024 and 2025: Non Operating Interest Expenses jumped 449.15% in 2024, then slumped 106.66% in 2025.
  • Over 5 years, Non Operating Interest Expenses stood at $1.4 million in 2022, then slumped by 69.7% to $413000.0 in 2023, then surged by 449.15% to $2.3 million in 2024, then plunged by 106.66% to -$151000.0 in 2025, then soared by 1117.22% to $1.5 million in 2026.
  • According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $1.5 million, $290000.0, and -$151000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Johnson & Johnson 642.37 Bn 621.61 Bn 17.26 Bn 281.00 Mn
2 AbbVie 446.97 Bn 440.40 Bn 12.70 Bn -
3 Merck 357.93 Bn 350.79 Bn 12.21 Bn -
4 Novartis Ag 267.54 Bn 259.85 Bn 11.24 Bn -462.00 Mn
5 Pfizer 156.64 Bn 144.94 Bn 10.94 Bn -
6 Sanofi 52.21 Bn 44.83 Bn 10.79 Bn -333.60 Mn
7 Revolution Medicines 42.91 Bn 42.91 Bn - 23.78 Mn
8 Incyte 24.61 Bn 20.08 Bn 1.57 Bn 582,000.00
9 United Therapeutics 21.55 Bn 18.89 Bn 683.80 Mn 2.90 Mn
10 CDT Equity 181,059.77 181,059.77 - 1.54 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.54 Mn
Mar 31, 2026 290,000.00
Dec 31, 2025 -151,000.00
Sep 30, 2025 189,000.00
Jun 30, 2025 1.02 Mn
Mar 31, 2025 969,000.00
Dec 31, 2024 2.27 Mn
Sep 30, 2024 708,000.00
Jun 30, 2024 2.34 Mn
Mar 31, 2024 625,000.00
Dec 31, 2023 413,000.00
Sep 30, 2023 249,000.00
Jun 30, 2023 1.11 Mn
Mar 31, 2023 293,000.00
Dec 31, 2022 1.36 Mn
Sep 30, 2022 118,000.00